Stoke Therapeutics, Inc.
DE ˙ DB ˙ US86150R1077
24,23 € ↓ -0,45 (-1,82%)
2026-06-05
DEL PRIS
SecurityDE:0GT / Stoke Therapeutics, Inc.
InstitutionTd Asset Management Inc
Latest Disclosed Ownership74,400 shares
Latest Disclosed Value $ 2,422,464
Td Asset Management Inc ownership in 0GT / Stoke Therapeutics, Inc.

On May 11, 2026 - Td Asset Management Inc filed a 13F-HR form disclosing ownership of 74,400 shares of Stoke Therapeutics, Inc. (DE:0GT) valued at $2,038,560 USD as of March 31, 2026. The entity filed a previous 13F-HR on October 27, 2023 disclosing 0 shares of Stoke Therapeutics, Inc.. The current value of the position is $1,802,712 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F STOKE THERAPEUTICS COM 86150R107 74,400 74,400 2,422 0.0011
2023-10-27 2023-09-30 13F STOKE THERAPEUTICS COM 86150R107 0 -26,186 -100.00 0 -100.00
2023-08-09 2023-06-30 13F STOKE THERAPEUTICS COM 86150R107 26,186 0 0.00 278 27.52 0.0003
2023-05-10 2023-03-31 13F STOKE THERAPEUTICS COM 86150R107 26,186 0 0.00 218 -9.54 0.0003
2023-02-07 2022-12-31 13F STOKE THERAPEUTICS COM 86150R107 26,186 0 0.00 242 -29.33 0.0003
2022-11-07 2022-09-30 13F STOKE THERAPEUTICS COM 86150R107 26,186 -8,528 -24.57 341 -25.71 0.0004
2022-08-04 2022-06-30 13F STOKE THERAPEUTICS COM 86150R107 34,714 0 0.00 459 -37.21 0.0005
2022-05-10 2022-03-31 13F STOKE THERAPEUTICS COM 86150R107 34,714 0 0.00 731 -12.24 0.0004
2022-02-10 2021-12-31 13F STOKE THERAPEUTICS COM 86150R107 34,714 5,600 19.23 833 12.42 0.0007
2021-11-09 2021-09-30 13F STOKE THERAPEUTICS COM 86150R107 29,114 0 0.00 741 -11.15 0.0008
2021-08-11 2021-06-30 13F STOKE THERAPEUTICS COM 86150R107 29,114 -7,900 -21.34 834 -42.00 0.0008
2021-05-14 2021-03-31 13F STOKE THERAPEUTICS COM 86150R107 37,014 5,673 18.10 1,438 -25.91 0.0016
2021-02-16 2020-12-31 13F STOKE THERAPEUTICS COM 86150R107 31,341 9,062 40.68 1,941 160.19 0.0024
2020-11-10 2020-09-30 13F STOKE THERAPEUTICS COM 86150R107 22,279 0 0.00 746 40.49 0.0010
2020-08-13 2020-06-30 13F STOKE THERAPEUTICS COM 86150R107 22,279 0 0.00 531 4.12 0.0008
2020-05-15 2020-03-31 13F STOKE THERAPEUTICS COM 86150R107 22,279 2,400 12.07 510 -9.41 0.0009
2020-02-11 2019-12-31 13F STOKE THERAPEUTICS COM 86150R107 19,879 0 0.00 563 31.85 0.0008
2019-11-07 2019-09-30 13F STOKE THERAPEUTICS COM 86150R107 19,879 19,879 427 0.0007
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.